CEO: Emil D. Kakkis

Sector: Healthcare
Industry:Biotechnology

Exchange: Nasdaq Global Select

Country: USA

Description: Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.


Key numbers

Market Capitalization:3291213870
Shares Outstanding: 57771000
Float: 53750369
Next Earning Date:2020-02-18
TTm EPS: -7.2331
TTm Dividend Rate:
200 days moving average:52.35
50 days moving average: 44.96
One day percent Change: -0.44



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,